Ivermectin Tablet
NDC Package 27241-293-73

11-digit billing NDC: 27241029373 · Billing unit: EA · 20 EA per package
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Ivermectin tablets is uSP are indicated for the treatment of the following infections:Strongyloidiasis of the intestinal tract. This formulation utilizes a tablet delivery system. Marketed by Ajanta Pharma Usa Inc., this product is identified by NDC 27241-293 and is authorized under FDA application ANDA218509.

Identification & Billing

NDC Package Code
27241-293-73
Package Description
2 BLISTER PACK in 1 CARTON / 10 TABLET in 1 BLISTER PACK
Product Code
27241-293
11-Digit Billing Format
27241029373
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
20 EA
RxNorm Crosswalk
RxCUI: 311207 - ivermectin 3 MG Oral Tablet

Clinical Specifications

Proprietary Name
Ivermectin
Non-Proprietary Name
Ivermectin
Substance Name
Ivermectin
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
IVERMECTIN 3 mg/1
Pharmacologic Class
Usage Information
Ivermectin tablets, USP are indicated for the treatment of the following infections:Strongyloidiasis of the intestinal tract. Ivermectin tablets are indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis. This indication is based on clinical studies of both comparative and open-label designs, in which 64% to 100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies.)Onchocerciasis. Ivermectin tablets are indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus.This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1,427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C).NOTE: Ivermectin tablets has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites.

Regulatory & Marketing

Labeler Name
Ajanta Pharma Usa Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA218509
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-07-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 27241-293-73 identifies a specific commercial package of 2 blister pack in 1 carton / 10 tablet in 1 blister pack of Ivermectin, a human prescription drug labeled by Ajanta Pharma Usa Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 20 billable units per package. This tablet is formulated for oral use and contains ivermectin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ajanta Pharma Usa Inc. on April 07, 2026. The current certification is valid through December 31, 2027.

How is this Ajanta Pharma Usa Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 27241029373. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 20 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
27241-293-73
11-Digit CMS (5-4-2)
27241-0293-73

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.